Chelsey McIntyre, PharmD, obtained her bachelor’s degree in genetics from the University of California, Davis and her Doctor of Pharmacy degree from Creighton University. She then went on to complete postgraduate residency training at the Children’s Hospital of Philadelphia, where she also worked as a drug information and clinical specialist. She has extensive experience in pediatrics, alternative medicine, drug information, and clinical content creation.
Recent WebMD content from Chelsey McIntyre, PharmD
- FDA Approves Jemperli for Certain Types of Rectal Cancer
- Leqvio for High Cholesterol
- FDA Approves Gazyva to Help Prevent Kidney Disease Relapses in Adults and Children Aged 2 or Older
- FDA Approves Emcitate to Treat Rare Thyroid Condition in Adults and Children
- FDA Approves Onswik, a Once-Weekly Insulin Shot for Type 2 Diabetes
- FDA Approves Fayuvi, First Gene Therapy for Children With Sanfilippo Syndrome Type A
- FDA Approves Kerendia for Adults With Type 1 Diabetes and Kidney Disease
- FDA Approves Mimrylo for Polycythemia Vera
- FDA Approves Besremi for Adults With Rare Blood Disorder
- Vinpocetine
- Wintergreen Oil
- Foxglove
- Fucus vesiculosus
- Patchouli Oil
- FDA Approves Genglycos, First Gene Therapy for Glycogen Storage Disease Type 1a
- FDA Approves Pasatru for Adults With Rare Bone Disease
- Cinchona
- Rauwolscine
- Bloodroot
- Colloidal Minerals
- Rue
- Betel nut
- Pantethine
- Laxogenin
- Kaolin Clay
- Histidine
- Ergothioneine
- Threonine
- Dimethylglycine (DMG)
- Beeswax
- Proline
- Serine
- FDA Approves Orzeyful (Oveporexton) for Adults With Narcolepsy Type 1
- Theacrine
- Piracetam
- Adrafinil
- Butcher’s Broom
- Iboga
- 1,4-Butanediol
- Tylenol With Naproxen: New Over-the-Counter Pill for 12-Hour Pain Relief
- FDA Approves Simtriyo, a New Type of Stimulant, for Adults and Children With ADHD
- FDA Approves Lytenava Eye Injection for Wet Age-Related Macular Degeneration
- Vanadium
- Agmatine
- FDA Approves Jideytro for Advanced ROS1-Positive Lung Cancer
- Androstenedione
- Ryaltris Nasal Spray Now Approved for Kids Ages 6-11 With Seasonal Allergies
- FDA Approves Lipfendra, the First Daily Pill of Its Kind to Lower Bad Cholesterol
- FDA Approves Revtorpyk to Help Treat Certain Form Advanced Breast Cancer
- FDA Approves At-Home Starting Dose for Alzheimer's Drug Leqembi
- FDA Approves Wilate to Help Prevent Bleeding in Young Children With von Willebrand Disease
- Headline: FDA Approves Sarclisa Escena, an Under-the-Skin Injection for Multiple Myeloma
- Trutakna: A New Weekly Shot to Help Adults With IgA Nephropathy
- Casgevy: FDA Expands One-Time Gene Therapy for Sickle Cell Disease and Beta Thalassemia to Children as Young as 2 Years
- FDA Approves Tryngolza, First Treatment to Reduce Acute Pancreatitis Risk in Severe Hypertriglyceridemia
- FDA Approves Tzield to Slow the Decline of Natural Insulin Production in People 8-17 Years Old With Newly Diagnosed Stage 3 Type 1 Diabetes
- Zaynich: FDA Approves New IV Antibiotic for Complicated Urinary Tract Infections in Adults
- FDA Approves Decnupaz, First Antibody-Drug Conjugate for Blastic Plasmacytoid Dendritic Cell Neoplasm
- Trimbow: A Triple-Combination Inhaler for Asthma Maintenance in Adults
- Fasenra: FDA Approves Under-the-Skin Shot to Help Reduce Flares in Hypereosinophilic Syndrome
